JOINT Corp — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
JOINT Corp reported Q2 2026 revenues of $15.2M (+14% YoY) with net income of $653K vs. $93K prior year. Adjusted EBITDA from continuing operations grew $1.4M to $1.5M; free cash flow improved to $1.9M (+420% YoY). The company repurchased 82,000 shares for $677K at $8.23/share and completed three regional developer territory buybacks. System-wide sales declined 3.7% to $180M; comp sales improved 140 bps to (2.8%). Clinic count stood at 941 (896 franchised, 45 company-owned/managed). Refranchising substantially complete: 32 Southern California clinics transferred, 4 Northern California signed, 6 Southeast transferred.
Why this rating
Solid profitability gains and FCF improvement signal successful transformation strategy. However, sales decline, negative continuing ops loss (-$251K), and 3.7% comp sales headwind temper enthusiasm. ~$1.4M EBITDA gain is ~0.8% of company market cap—material but not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.